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Aims: Porphyrin-loaded core-shell nanoparticles are engineered as an in vivo ultrasound 
responsive system, a radio-tracer or a magnetic resonance (MR) imaging agent, suitable for 
the selective treatment of solid tumors and imaging analyses. Materials & methods: Poly 
methyl methacrylate nanoparticles (PMMANPs) are loaded with meso-tetrakis (4- 
sulphonatophenyl) porphyrin (TPPS) for anticancer sonodynamic treatment, or with 64Cu- 
TPPS for positron emission tomography biodistribution studies or with Mn(III)-TPPS for MR 
tumor accumulation evaluation. Results: PMMANPs exhibit ease of functionalization with 
negatively charged molecules and favorable biodistribution. In vivo TPPS-PMMANPs 
demonstrate ultrasound responsiveness in a syngeneic rat breast cancer model by MR 
analyses of pre- and  post-treatment  tumor volumes.  Conclusion: TPPS-PMMANPs is  a 




In the last decades, one of the disciplines that mostly benefited from nanotechnology is 
oncology. Nanoparticle systems have been used in several studies aimed to investigate their 
potential as diagnosis and therapy tools [1]. In fact, one of the most fascinating aspect of 
nanoparticles relies on the possibility to manipulate molecules and supramolecular structures 
for producing objects with programmed functions, such as the ability to preferentially 
accumulate in the tumor vessels, to convey higher drug concentration at the target site and to 
provide a multi-purpose loading capabilities [2,3]. In addition, nanoparticles have been 
investigated as therapeutic drug-delivery systems, as contrast agents for magnetic resonance 
imaging (MRI) and as tumor visualizing agents during surgery [4,5]. Several types of 
nanoparticle platforms have also been evaluated for theranostic applications combining the 
modalities of therapy and diagnosis to deliver the drug and to allow performing diagnostic 
imaging at the same time and within the same macro-molecular system [6]. This approach 
allows to potentially overcome undesirable differences in biodistribution that currently exist 
between imaging and therapeutic agents, with the consequent advantage to allow the long- 
term hope of gaining the ability to tune therapy with heretofore unattainable control. In the 
field of cancer diagnosis, MRI and positron emission tomography (PET) are the most 
widespread imaging techniques able to provide a three-dimensional image of the body 
functional processes (MRI) and morphological/physiological information on body’s organs 
(PET) [7,8]. In this regard, nanotechnology might provide a more sensitive and accurate 
approach able to manage diagnosis, staging, treatment and monitoring of cancer with the same 
hybrid technology [9,10]. 
Thus, further significant progresses in anticancer therapeutic options will also depend on 
efforts devoted to the development of novel nanotechnological-based anticancer treatments. In 
this  regard  in  a  previous  study  we  developed  poly-methyl  methacrylate  nanoparticles 
(PMMANPs) carrying the meso-tetrakis (4-sulfonatophenyl) porphyrin (TPPS) that were able 
	  
to improve the porphyrin sonodynamic activity in an in vitro two- and three-dimensional 
model of cancer [11]. The sonodynamic anticancer approach refers to the use of ultrasound, 
i.e, mechanical vibration above the threshold of human hearing (20 kHz), as an external 
stimulus to trigger the cytotoxicity of chemical agents, i.e., sonosensitizers. From a clinical 
point of view, ultrasound can be distinguished in diagnostic ultrasound generally with a 
frequency range between 3.0-30.0 MHz and therapeutic ultrasound with a frequency range 
between 0.5-3.0 MHz [12]. The latter is usually generated by applying an alternating voltage 
across a piezoelectric material and a focused ultrasound beam is directed, harmlessly, across 
the skin and intervening tissues towards the target. In the so-called high intensity focused 
ultrasound (HIFU), a combination of mechanical stresses and thermal insult at microscopic 
level induce cell necrosis [13]. Remarkably, the energy level sufficient to cause a temperature 
rise able to produce instantaneous cell death is reached only at the center of the beam. A wide 
range of tumor types can be targeted with HIFU. In fact, this technique has been taken into 
account for palliative treatment of symptoms or for local tumor control of patients with poor 
prognoses [13]. HIFU is now being used clinically to treat solid tumors, both malignant and 
benign, including prostate, liver, breast, kidney, bone, pancreas and soft-tissue sarcoma [14– 
16]. In addition to HIFU, a different anticancer ultrasound-based approach, namely 
sonodynamic therapy (SDT), is under investigation to promote, deeply in the tissues, the 
activation of sonosensitizers to induce a more selective cancer cell death [17]. The feasibility 
of this approach has been already demonstrated at preclinical level on some experimental 
tumor models [18–23]. 
In SDT, the sensitizer is believed to be activated by inertial cavitation, a process induced by 
ultrasounds that induces the formation of microscopic air bubbles within the tissues’ liquids, 
which ultimately oscillate, expand and violently collapse. The cellular membrane is 
intrinsically  capable  of  absorbing  mechanical  energy  from  the  ultrasound  field  and  to 
transform it into expansions and contractions of the intramembranous space [24]. When the 
	  
acoustic intensity is sufficient to induce microscopic air bubbles to collapse quickly, a great 
release of energy might occur, inducing a series of chemical reactions around the bubbles and 
the sensitizer. Accordingly, an excess amounts of reactive oxygen species (ROS) such as 
superoxide anion (O2−), hydrogen peroxide (H2O2) and hydroxyl radical (HO−), can be formed. 
These species are than able to damage cells by peroxidizing lipids and disrupting DNA and 
 
proteins, but also to exert signaling functions and modulate gene transcription, thereby 
resulting in cellular dysfunction and apoptosis [25]. On this topic, we first introduced the use 
of shock wave (SW) to trigger sonosensitizer’s cytotoxicity, since pulsed ultrasound generates 
significantly less thermal effect than continuous ultrasound [26]. 
Among the sonosensitizers, porphyrin-type molecules have been extensively applied in SDT 
[27]. In addition, the use of nanoparticles as carriers of the sonosensitizer might provide an 
additional advantage with respect to nanoparticle-mediated drug delivery. Indeed, in the case 
of SDT, nanoparticles can represent the nucleation sites that participate in the formation of 
bubbles thus reducing the threshold of intensity required for cavitation, the phenomenon 
underlying the sonodynamic activity [28,29]. Moreover, moving our experiments in in vivo 
model, biodistribution studies are also needed to determine the in vivo TPPS-PMMANPs fate. 
So, in the present study, we aim to investigate our nanoparticle system, properly decorated 
with TPPS, 64Cu-TPPS- and Mn(III)-TPPS to distinctly functions in vivo as sonosensitizing 
 
system, radio-tracer and MR imaging agent, respectively (Figure 1). 
	  






2-(Dimethylamino)ethyl methacrylate (DMAEMA), 1-bromooctane, 2,2’-Azobis(2- 
methylpropionamidine) dihydrochloride (AIBA), methyl methacrylate (MMA, 99.0%) 
(distilled before use), TPPS, Mn(III)-TPPS, Cu(CH3CO2)2, McCoy’s 5A modified medium, 
fetal bovine serum (FBS), penicillin, streptomycin, Hank’s-balanced salt solution (HBSS), 
formalin, xylene and hematoxylin-eosin were purchased from Sigma-Aldrich (Schnelldorf, 
DE) and used without further purification unless otherwise stated. Allprotect Tissue Reagent, 
AllPrep® DNA/RNA/protein Kit, QuantiTect® Reverse Transcription Kit and QuantiTect 
Primer Assay were purchased from Qiagen (Milano, Italy). Quant-iT™ RNA Assay Kit was 
purchased from Invitrogen (Milano, Italy). RNA 6000 Nano Kit was purchased from Agilent 




§ TPPS, Mn(III)-TPPS or 64CuTPPS-PMMANPs synthesis and characterization 
TPPS-PMMANPs were obtained as previously described.[11] Mn(III)-TPPS-PMMANPs 
synthesis and characterization was performed according to the same procedure used for the 
synthesis of TPPS-PMMANPs by replacing TPPS with commercially available Mn(III)-TPPS. 
Our cyclotron facility provides 64Cu isotope on a routine basis for research purposes, using a 
target system developed in collaboration with Tema Sinergie (Faenza, Italy). 64Cu was 
produced on a GE PETTrace cyclotron by the reaction 64Ni(p,n) 64Cu using an enriched 64Ni 
target electroplated on a gold disk. 64CuCl2 was recovered from the target and converted to 
64Cu-acetate by dissolving the 64CuCl2 in ammonium acetate (0.1 M; pH 5.5), followed by 
evaporation to dryness. TPPS was labelled with 64Cu following conditions optimized with 
“cold” Cu(CH3CO2)2 [30]. 
	  
64Cu-TPPS preparation was performed as follows: 40 µl of a 3M solution of sodium acetate 
(NaOAc) were added to 160 µl of 64Cu mother solution (5.46 mCi) followed by 25 µl TPPS 
water solution (2mg/mL) and 103 µl of physiological solution. The mixture was then vortexed 
for 10 sec and analysed by TLC (SiO2; eluent: CH2Cl2/MeOH=1/2) and 64Cu was detected on 
Instant Imager system (98% of 64Cu chelation; radioactivity of the solution 1.66 mCi). 64Cu 
amount was counted in a Capintec CRC15 PET Radioisotope Calibrator to calculate the 
activity of the product. 
 
64Cu-TPPS-PMMANPs preparation was performed as follows: 60 µl of a 3M solution of 
sodium acetate (NaOAc) were added to 240 µl of 64Cu mother solution (5.3 mCi) followed by 
25 µl TPPS water solution (2 mg/mL), 33.1 µl of PMMANPs (5 mg/mL) and 141.9 µl of 
physiological solution. The resulting solution was vortexed for 20 sec, filtered on a 0.1 µm 
filter for centrifuge and radioactivity was measured (1.72 mCi). The particles solution was 
then centrifuged (3000xG) for 15 min and filtered. The supernatant did not display any 
radioactivity. 64Cu amount was counted in a Capintec Radioisotope Calibrator to calculate the 
specific activity of the product. 
 
 
§ Positron emission tomography studies 
 
Female Balb/c mice 8 weeks-old (Charles River laboratories, Milano, Italy) were 
intravenously (iv) injected with 8.3 MBq 64Cu-TPPS or 64Cu-TPPS-PMMANPs 
[corresponding to 10 mg/Kg body weight (bw) TPPS] and at 1, 4 and 18 h static scans were 
acquired for 20 min using a small-animal PET system (GE, eXplore Vista DR; General 
Electric, Milwaukee, WI, USA) with the animals under isoflurane anesthesia. The images 
were reconstructed by a 2-dimensional ordered-subsets expectation maximum (OSEM) 
algorithm and read in three planes (axial, sagittal, and coronal). For each microPET scan, 
regions of interest were drawn over the major organs on the decay-corrected whole-body 
	  
coronal images. The radioactivity concentration (accumulation) within the brain, liver, spleen 
and kidneys were obtained from the mean value within the multiple regions of interest and 
then converted to standardized uptake value (SUV, corrected for body weight and injected 
radioactivity). 
Twenty-four hours after the intravenous administration of 8.3 MBq 64Cu-TPPS or 64Cu-TPPS- 
 
PMMANPs the animals were sacrificed and the organs of interest were collected, weighed, 
and processed for radioactivity counting using a c-counter with decay correction. The 
radioactivity uptake was expressed as radioactivity per gram of tissue (kBq/g). 
 
 
§ Breast cancer model 
 
The rat mammary adenocarcinoma cell line, Mat B III (ATCC, Rockville, MD, USA), was 
maintained in McCoy’s 5A modified medium supplemented with 10% FBS, 100 units/mL 
penicillin and 100 µg/mL streptomycin. Cells were cultured at +37 °C in a humidified 
atmosphere containing 5% CO2. Before inoculation, Mat B III cells were washed with HBSS 
and centrifuged at 1500 rpm for 5 min. Cell pellets (1 × 106 cells) were suspended in 0.5 mL 
 
saline and injected using 1 mL insulin syringes orthotopically into the abdominal mammary 
fat pad of inbred female 12 weeks-old Fisher 344 rats (Charles River laboratories) under 
isoflurane anesthesia. Following tumor-cell implantation, all animals were examined daily for 
the development of tumors for up to 12 days. The animals were randomly assigned to 
treatment groups, with at least four animals per group. 
 
 
§ Magnetic resonance imaging evaluations 
 
Manganese-enhanced MRI was performed at day 9 after tumor cell inoculation to evaluate 
Mn(III)-TPPS or Mn(III)-TPPS-PMMANPs tumor accumulation to pick the right time for 
ultrasound exposure while for evaluating the sonodynamic treatment efficacy tumor bearing 
	  
rats were imaged at day 8 (24 h pre-treatment) and day 11 (48 h post-treatment) from Mat B 
III cell inoculation. 
MRI was conducted using a dedicate whole body rat coil in a high field (7T) MRI scanner 
(Bruker, PharmScan, Germany) and rats were supplied with 1-2% isofluorane in air and O2 
for anesthetization (animals’ respiration rate was monitored throughout the entire imaging 
analysis with a sensor connected to an ECG/respiratory unit). Spin echo (RARE) imaging 
(TR/TE/NEX = 3000/8.5/2, slices thick 1.5 mm, FOV 50 mm, matrix 256 x 256; 15 slices, 
imaging time = 2.5 min) was used to calculate tumor volume and to analyse tumor 
morphology. 
Serial T1-weighted MR scans with multislice spin-echo sequence (TR/TE =500/12 ms, 
number of averages NA = 2), were collected before Mn(III)-TPPS as free or nanoparticle 
formulation were intravenously injected and after 1, 4 and 24 h. 
The percentage enhanced signal on tumor, liver, spleen and kidneys at 1, 4 and 24 h from the 
iv administration of 10 mg/kg bw of Mn-TPPS as free or nanoparticle formulation were 
obtained by control to noise ratio percentage [CNR(T1)%] calculations which correlates 
CNR(T1) post-contrast to the corresponding pre-contrast value. CNR(T1) is defined as the 
difference between the averaged imaging coefficient within the region of interest (ROI) and 
the differences within the background region, divided by the averaged imaging coefficient 
variation in the background. 
 
 
§ Sonodynamic treatment 
The tumor volumes of both control and experimental groups were monitored at day 8 (24 h 
pre-treatment) and at day 11 (48 h post-treatment) by MRI. The sonodynamic treatment was 
performed when the subcutaneous tumors reaching 300-500 mm3 in volume typically in nine 
days. Control and experimental animals were treated on day 9 with one single iv injection into 
the tail vein of saline or 10 mg/kg bw TPPS or TPPS-PMMANPs, SW alone (0.88 mJ/mm2, 
	  
500 impulses, 4 impulse/sec), or a combination of TPPS or TPPS-PMMANPs and SW (10 
mg/kg bw iv 4 h before SW exposure at 0.88 mJ/mm2, 500 impulses, 4 impulse/sec). All 
control and experimental animals were sacrificed at the end of the study (day 12), examined 
and scored for the development of macroscopic tumor metastases in various tissues. Primary 
tumor tissues were removed in 10% buffered formalin for histological examination and in 
Allprotect Tissue Reagent for mRNA gene expression evaluation. The piezoelectric shock 
wave generator Piezoson 100 (Wolf, Germany) was used for the sonodynamic treatment and 
the energy at the focal point is defined as energy flux density (EFD) per impulse, recorded as 
mJ/mm2. It is assumed an elliptical focus cigar with a length of 10 mm in the direction of the 
axis of the shock wave propagation and a diameter of 2.5 mm perpendicular to this axis. 
Tumor bearing rats were anesthetized with 1-2% isofluorane in air and O2, fixed to a board in 
a supine position with the tumor upwards and the hair over the tumor was shaved and 
ultrasound gel applied to the naked skin. The transducer was placed in close contact with the 
tumor. The position and the angle of the rat were adjusted to locate the tumor at the focal spot 
and, thus, allow the focused ultrasound to propagate throughout the tumor mass. All animals 
were then placed on a warm blanket and observed until their complete recovery before putting 
them back into their cages. 
 
 
§ Histopathological analysis 
 
Tumor samples 12 days after Mat B III cell inoculation (72 h post-treatment) were fixed in 
10% formalin, blocked in paraffin resin, cut in 4 µm, deparaffinized in xylene and rehydrated 
with alcohol following standard protocols. Sections were then stained with hematoxylin-eosin 
for histological examination and visualized by light microscopy (Leica DM600, Wetzlar, 
Germany). The morphological features of apoptosis and necrosis such as the presence of 
edema, inflammation, red blood cells extravasation in at least ten random fields per slide at 
	  
40x magnification were evaluated. All examinations were accomplished in a blind test 
without prior knowledge of the group sample. 
 
 
§ Real Time RT-PCR analyses 
 
Total RNA was isolated from tumor samples 12 days after Mat B III cell inoculation (72 h 
post- treatment). Briefly, tumor samples were collected in Allprotect Tissue Reagent and 
stored at -80 °C. Total RNA was then obtained by the AllPrep® DNA/RNA/protein Kit 
according to the manufacture instructions. The total RNA concentration (µg/mL) was 
determined by the fluorometer Qubit (Invitrogen, Milano, Italy) and the Quant-iT™ RNA 
Assay Kit; calibration was done applying a two-point standard curve, according to the 
manufacturer’s instructions. The integrity of the RNA samples was determined by the total 
RNA 6000 Nano Kit by the Agilent 2100 Bioanalyzer (Agilent Technologies). Real-time 
reverse transcriptase (RT)-PCR analysis was carried out using 500 ng of total RNA, which 
was reverse transcribed in a 20 µL cDNA (complementary DNA) reaction volume, using the 
QuantiTect® Reverse Transcription Kit, according to the manufacturer’s instructions; 12.5 ng 
of cDNA was used for each 10 µL real-time RT-PCR reaction. Quantitative RT-PCR was 
performed using the SsoFast™ EvaGreen. QuantiTect Primer Assay was used as the gene- 
specific primer pair for APAF1 (cat n° QT01611225), BAD (cat n° QT00190407), BAX (cat n° 
QT01081752), HIF1A (cat n° QT00182532), MMP9 (cat n° QT00178290), NFE2L2 (cat n° 
QT00183617), NQO1 (cat n° QT00186802), RNR1 (cat n° QT00199374), and TP53 (cat n° 
QT00193522). The transcript of the reference gene ribosomal 18s and 28s RNA (RRN1) was 
used to normalize mRNA data, and real-time PCR was performed by a MiniOpticon™ Real 
Time PCR system (Bio-Rad). The PCR protocol conditions were as follows: HotStarTaq 
DNA polymerase activation step at +95 °C for 30 sec, followed by 40 cycles at +95 °C for 5 
seconds and +55 °C for 10 sec. All runs were performed with at least three independent 
cDNA preparations per sample, and all samples were run in duplicate. At least two non- 
	  
template controls were included in all PCR runs. The quantification data analyses were 
performed using the Bio-Rad CFX Manager Software version 1.6 (Bio-Rad) according to the 
manufacturer’s instructions. These analyses were performed in compliance with the MIQE 




§ Statistical analysis 
 
Results are expressed throughout as the average value ± standard deviation (SD). Statistical 
analyses were performed with Graph-Pad Prism 5.0 software (La Jolla, CA, USA); one-way 
ANOVA and Bonferroni’s post test were used to calculate the threshold of significance. 






§ TPPS, Mn(III)-TPPS or 64Cu-TPPS- PMMANPs 
 
PMMANPs synthesis, characterization and loading with TPPS and Mn(III)-TPPS was 
performed as previously described [11]. PMMANPs were characterized by an average 
hydrodynamic diameter of 93 ± 1.4 nm, with 265 μmol of quaternary ammonium bromides 
per gram of nanospheres and a ζ-potential of 38.8 ±	 2.4 mV. The stability of the TPPS- 
PMMANPs system was evaluated by mimicking physiological conditions using further PBS 
treatment (150 mM) at + 37 °C and cell growth culture medium as the washing solutions. 
64Cu-TPPS-PMMANPs were straightforwardly obtained by simple mixing of the PMMANPs 
water suspension and freshly prepared 64Cu-TPPS. 
 
 
§ Sonosensitizing system biodistribution 
The PET analysis of the biodistribution of 64Cu-TPPS or 64Cu-TPPS-PMMANPs at different 
time point from iv administration in healthy mice, highlighted that the nanoparticle system 
was not able to cross the blood brain barrier (BBB). This was proved through the PET 
analysis of its biodistribution in vivo, as a negligible signal was detected in the brain (Figure 
2A-B). On the other hand, a strong increase of 64Cu-TPPS-PMMANPs uptake was found in 
the liver and spleen over time, suggesting a low rate of renal excretion associated to a high 
trapping in the reticulo-endothelial system (Figure 2A). The renal excretion of 64Cu-TPPS was 
higher since the uptake in the kidney was significant over time whilst the renal excretion of 
64Cu-TPPS-PMMANPs was significant only 1 h after the iv administration. This was 
confirmed at the ex-vivo analysis performed 24 h after the iv administration. So a higher 
trapping of the 64Cu-loaded nanoparticles was found in the liver and spleen as compared to 
64Cu-TPPS and a higher uptake of 64Cu-TPPS in the kidney was found as well (Figure 2B). 
	  
§ Sonosensitizing system tumor accumulation 
 
In order to evaluate further application of our porphyrin-based nanoparticle system the time 
scheduling for ultrasound exposure was performed by a Mn(III)-enhanced magnetic 
resonance analysis of the tumor after the iv administration of Mn(III)-TPPS or Mn(III)-TPPS- 
loaded onto nanoparticles shell, Mn(III)-TPPS-PMMANPs. As reported in Figure 3 the MR 
signal expressed as the percentage of control to noise [CNR(T1)%] at the tumor level had a 
different trend depending to the Mn(III)-TPPS administration form. Indeed, the highest 
CNR(T1)% in the tumor was recorded at 24 h after the i.v. administration of Mn(III)-TPPS, 
(Figure 3). As it has been reported, TPPS is well accumulating in tumor tissue and localized 
mostly in tumor stroma [32]. Mn(III)-TPPS-PMMANPs determined a significant increase of 
the CNR(T1)% already at 1 h after the iv administration in the tumor and in spleen (Figure 3). 
The analysis of the animals treated with Mn(III)-TPPS-PMMANPs displayed an almost equal 
CNR(T1)% value at 1, 4 and 24 h upon iv administration (Figure 3). We observed persistent 
but lower CNR(T1)% values after the Mn(III)-TPPS-PMMANPs with respect to the Mn(III)- 
TPPS iv administration in the tumor and a higher signal in liver and spleen and the lower 
signal in kidneys after Mn(III)-TPPS-PMMANPs administration (Figure 3). We then decided 




§ Sonosensitizing system anticancer activity 
 
To investigate the effect of the sonodynamic treatment with TPPS or TPPS-PMMANPs on 
the tumor growth, tumor volumes were determined by MR 24 h pre- and 48 h post- 
sonodynamic treatment. Ultrasound exposure as shock wave mode was performed at day 9 
from tumor inoculation, i.e. when the tumors reached a volume of approximately 500 mm3. 
Figure 4 shows a significant reduction of tumor volumes in the group treated with the 
	  
nanoparticles formulation and shock waves, confirming our hypothesis of an enhancement of 
the porphyrin sonodynamic activity when loaded onto the nanoparticles. 
The histological examinations of tumor sections of animals treated with TPPS-PMMANPs 
and SW highlighted a strong increase of necrotic and apoptotic features, while no injury of the 
blood vessels with blood cells extravasation respect to untreated animals was  observed 
(Figure 5A-B). 
As the controlled and targeted specific ROS generation can be the effector of the 
sonodynamic anticancer activity, we looked at the mRNA levels in tumor tissue of the group 
treated with TPPS-PMMANPs plus SW. Indeed, with respect to untreated group, we observed 
an increased expression of oxidative stress related genes such as the transcription factor 
Hypoxia Inducible Factor 1 Alpha Subunit (HIF1A), the reductase NAD(P)H Dehydrogenase, 
Quinone 1 (NQO1) and the cytochrome c-dependent apoptosis activation mediator Apoptotic 
Peptidase Activating Factor 1 (APAF1). Moreover, a significant reduction of the apoptosis 
regulator BCL2-Associated X Protein (BAX) and of the extracellular matrix endopeptidases 




Nanotechnology works towards satisfying desired objectives using materials and device 
whose valuable properties owe to some specific nanometer-scale elements of their structures, 
making this discipline extremely dynamic and highly application oriented [33]. In this regard 
we considered an innovative nanoscale platform able to improve a less investigated but, in our 
opinion, promising therapeutic approach in oncology, i.e., sonodynamic therapy. Indeed 
recently, external stimuli mediated treatments, relying on the synergistic effects of two 
components of either chemical or physical nature, received considerable attention in cancer 
therapy due to their lower systemic toxicity and higher selectivity as they are based on the 
preferential tissues uptake and/or retention of a sensitizer which is subsequently activated by 
light (PDT) or ultrasound (SDT). Although the basic principle of STD may be related to PDT, 
since in both mechanisms a non-toxic chemical compounds must be first activated before 
becoming cytotoxic, the use of ultrasound as external stimulus (STD) might represent a great 
advantage in terms of tissues penetration ability. Indeed, ultrasound energy are able to enter 
the target site deeply within the tissues, thus overcoming one of the major drawbacks of PDT, 
i.e., light’s relatively limited capacity to penetrate human tissue [34,35]. Noteworthy is the 
fact that attention is now increasingly focused towards the possibility of enhancing the cancer- 
specific immunity upon direct ultrasound-induced treatment [35,13]. 
As confirmed by the rapidly expanding knowledge on the fundamental mechanisms of SDT, 
the development of ultrasound selective sensitizers is one of the most essential factors in SDT. 
Discovery and development of novel sensitizers are becoming the major focus of recent 
investigation in this field [27]. In order to improve the sonodynamic cancer therapy, we 
developed a core-shell polymer-based nanoparticle, namely PMMANPs, carrying porphyrin 
to be in vivo triggered by ultrasound applied as shock wave mode. In fact, the nanoparticles 
mediated drug delivery concept is not the only factor that can enhance SDT [20]. Indeed, the 
existence of appropriate nanoparticles in the milieu might provide nucleation sites decreasing 
	  
the cavitation threshold that must be reached through ultrasound exposure [36,37]. Moreover, 
the ease of the manipulation and loading procedure of our PMMANPs, along with their high 
stability under forced release conditions, make these nanoparticles particularly attractive for 
theranostic applications. In principle, thanks to their high external shell charge density, the 
sequential post-loading of different negatively charged compounds, e.g. sulfonates, is easily 
achievable, thus allowing the preparation of nanocarriers either with sensitizers, imaging 
agents and radiotracers for theranostic applications. With regard to MRI and taking into 
account the increasing concerns of nephrogenic system fibrosis caused by gadolinium-based 
blood poll agents in patients with renal disease or with recent liver transplant, we selected 
Mn(III) as the T1 contrast agent for MR analysis [38,39]. 
The sonodynamic treatment was performed by ultrasound applied as shock wave mode to 
improve the non-thermal interactions of ultrasound energy with biological tissue that are 
primarily mediated by cavitation. Moreover, the use of pulsed ultrasound as shock wave well- 
fit with the theory of the “bilayer sonophore” affirming that the bilayer membrane is capable 
(under appropriate conditions) of transforming the (millimetre wavelength) oscillating 
acoustic pressure wave into (nanometric and micrometric) intracellular deformations able to 
induce intracellular cavitation [24]. 
The ultrasound responsiveness of the TPPS-PMMANPs was confirmed by a significant 
decrease in the volume of the tumor masses, i.e., up to the fifty percent, for the sonodynamic 
treatment with TPPS-PMMANPs as shown in Figure 4. Moreover, the observed persistent 
TPPS-PMMANPs tumor accumulation recorded by MR analysis, might be highly beneficial 
for programming repeated ultrasound exposure, without need of multiple administrations 
(Figure 3). Finally, to our knowledge, this work highlighted for the first time the in vivo 
modulation of a panel of genes involved in the ROS mediated cell death by sonodynamic 
treatment. Indeed, in tumors treated with TPPS-PMMANPs and SW, it was observed a 
	  
significant ROS-induced overexpression of APAF1, HIF1A and NQO1 genes that might lead 





In summary, a multifunctional nanoparticle system carrying meso-tetrakis (4-sulfonatophenyl) 
porphyrin was subsequently in vivo applied as sonosensitizing system in sonodynamic 
anticancer treatment, as radio-tracer in PET biodistriobution studies and as MR imaging agent 
in tumor accumulation studies. Our results clearly indicate that the in vivo sonosensitizing 
system was able to efficiently induce selective ultrasound mediated cancer cell death. 
Moreover, we provided an in vivo proof-of-concept of the viability of PMMANPs as valuable 





Investigations on the contemporary multiple loading of TPPS, Mn(III)-TPPS and 64Cu-TPPS 
on PMMANPs are actively underway in our laboratories for future theranostic applications. 
Such an innovative nanoscale platform would allow to set personalized treatment schedules 
for the anticancer sonodynamic therapy by imaging modalities that at the same time might be 
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§ The use of a single nano-object, i.e. PMMANPs, as versatile and easily functionalizable 
platform for the multiple loading of the sonosensitizer, the imaging agent and the 
radiotracer 
§ The use of ultrasound applied as shock wave mode to induce the sonosensitizing system 
activation 
§ The evidence of in vivo anticancer activity of the sonosensitizing system triggered by 
ultrasound through sonodynamic activity promoting oxidative stress-mediated cell death 
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Figure 1. Representation of PMMANPs, TPPS, Mn(III)-TPPS and 64Cu-TPPS. 
 
Figure 2. PET analysis of 64Cu-TPPS and 64Cu-TPPS-PMMANPs biodistribution in 
healthy mice. The radioactivity uptake in brain, liver, spleen and kidneys was expressed as 
standardized uptake value (SUV) after 1, 4 and 18 h of iv administration of 10 mg/kg bw 
64Cu-TPPS as free or nanoparticle formulation (A). The ex-vivo tissue radioactivity was 
expressed as kBq per gram of tissue 24 h after the iv administration of 10 mg/kg bw 64Cu- 
TPPS as free or nanoparticle formulation (B). Data are expressed as mean ± SD of at least two 




Figure 3. MRI analysis of Mn(III)-TPPS and Mn(III)-TPPS-PMMANPs biodistribution 
in Mat B III/ Fisher 344 breast cancer model. The manganese-enhanced MRI were 
determined at 1, 4 and 24 h from the iv administration of 10 mg/kg bw Mn(III)-TPPS as free 
or nanoparticle formulation at day 9 after tumor cell inoculation. The percentage enhanced 
signal of tumor, liver, spleen and kidneys were obtained by the contrast to noise ratios (CNR) 
calculations. Data are expressed as mean ± SD of at least two separate experiments each with 
at least four animals per group. 
 
 
Figure 4. Effect of sonodynamic treatment on Mat B III/ Fisher 344 tumor growth. Rats 
with growing tumors were treated with TPPS or TPPS-PMMANPs plus SW (10 mg/kg b.w. 
i.v. and 0.88 mJ/cm2 for 500 impulses, 4 impulses/sec, respectively) at day 9 from tumor cells 
inoculation and tumor volumes were determined by MR at day 8 and 11. Representative T2- 
weighted images of control (A and B) and TPPS-PMMANPs plus SW treated (C and D) rats 
at day 8 (24 h pre-treatment, A and C) and 11 (48 h post-treatment, B and D). The relative 
	  
tumor volumes, i.e. the ratio between volumes at day 11 and at day 8, of each experimental 
groups are reported as mean ± SD for at least three separate experiments each with at least 
four animals per group (E). Statistical significance versus tumor volumes at day 8, *** p < 
0.001. 
 
Figure 5. Effect of sonodynamic treatment with TPPS-PMMANPs on Mat B III/Fisher 
344 tumor features. Representative hematoxylin-eosin section images of control (A) and 
TPPS-PMMANPs plus  SW  treated  (B) rats 72  h  from  the sonodynamic treatment  (10x 
magnification). Rats with growing tumors were treated with TPPS or TPPS-PMMANPs plus 
SW (10 mg/kg bw iv and 0.88 mJ/cm2 for 500 impulses, 4 impulses/sec, respectively) at day 9 
from tumor cells inoculation. mRNA expression analysis 48 h after the sonodynamic 
treatment (C). RNR1 (ribosomal RNA 18S and 28S) was used as a reference gene to 
normalize the data. The sonodynamic therapy-induced alterations in mRNA levels were 
compared with those of the control, ie untreated rats, stated as 1 and are shown by the dotted 
line. Data are reported as mean ± SD for at least three separate experiments each with at least 
four animals per group. Statistical significance versus control, * p < 0.05, ** p < 0.01. 
